Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trimodulin - Biotest

Next Previous
Drug Profile

Trimodulin - Biotest

Alternative Names: BT 588; BT086; IgM concentrate - Biotest; Trimodulia

Latest Information Update: 30 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotest AG
  • Class Anti-infectives; Anti-inflammatories; Antivirals; Polyclonal antibodies
  • Mechanism of Action Endotoxin inhibitors; Immunostimulants; Phagocyte stimulants; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia; COVID 2019 infections

Most Recent Events

  • 20 Jun 2023 Phase-III clinical trials in Community-acquired pneumonia (Adjunctive treatment) in USA, Czech Republic, Belgium (IV) (NCT05722938)
  • 10 Feb 2023 Biotest AG plans a phase III trial for Community-acquired pneumonia (Adjunctive therapy, In adults, In the elderly) in March 2023 (IV, Infusion) (NCT05722938)
  • 06 Sep 2022 Phase-III clinical trials in COVID-2019 infections Adjunctive treatment) in Hungary (IV) (EudraCT2022-000736-37)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top